WaveMan
WaveMan · Company
IBAC · Ib Acquisition Corp.
> Search tickers & screens ⌘K
LIVE
← All companies

IBAC IB Acquisition (IBAC) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Services-commercial physical & biological research · CIK 0001998781
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
4
13F, latest reported quarter

IB Acquisition insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for IB Acquisition Corp. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
AQR Arbitrage LLC
SELL
2026-03-25 SECtraded 2026-03-23
6,262
$67.6K
+1.7%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Oct 9, 2025.
  • The trade is 96.0% of the 6,524 shares held after it.
  • 1 other insider sold within 30 days.
  • 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider AQR Arbitrage LLC sold about $67.6K of IBAC on Mar 23, 2026; 1 other insider sold within 30 days and 4 funds added in the latest 13F quarter.
AQR Arbitrage LLC
SELL
2026-03-25 SECtraded 2026-03-23
40,144
$433.6K
+1.7%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Oct 9, 2025.
  • The trade is 96.0% of the 41,825 shares held after it.
  • 1 other insider sold within 30 days.
  • 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider AQR Arbitrage LLC sold about $433.6K of IBAC on Mar 23, 2026; 1 other insider sold within 30 days and 4 funds added in the latest 13F quarter.
AQR Arbitrage LLC
SELL
2026-03-25 SECtraded 2026-03-23
56,145
$606.4K
+1.7%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Oct 9, 2025.
  • The trade is 96.0% of the 58,496 shares held after it.
  • 1 other insider sold within 30 days.
  • 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider AQR Arbitrage LLC sold about $606.4K of IBAC on Mar 23, 2026; 1 other insider sold within 30 days and 4 funds added in the latest 13F quarter.
AQR Arbitrage LLC
SELL
2026-03-25 SECtraded 2026-03-23
1,623
$17.5K
+1.7%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Oct 9, 2025.
  • The trade is 96.0% of the 1,690 shares held after it.
  • 1 other insider sold within 30 days.
  • 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider AQR Arbitrage LLC sold about $17.5K of IBAC on Mar 23, 2026; 1 other insider sold within 30 days and 4 funds added in the latest 13F quarter.
AQR Arbitrage LLC
SELL
2026-03-25 SECtraded 2026-03-23
25,087
$270.9K
+1.7%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Oct 9, 2025.
  • The trade is 96.0% of the 26,138 shares held after it.
  • 1 other insider sold within 30 days.
  • 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider AQR Arbitrage LLC sold about $270.9K of IBAC on Mar 23, 2026; 1 other insider sold within 30 days and 4 funds added in the latest 13F quarter.
66 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 61 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
4 funds bought in last quarter
below 97% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
$7.9M repurchased, FY to 2026-06-30
below 76% of Pharma & Biotech
Short interest
0.2% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 90% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IBAC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+3.9%12M
-0%+4%+7%+11%2025-102025-122026-022026-042026-062026-082026-10 2026-03-23 · AQR Arbitrage LLC sold $1.5M2026-03-23 · AQR Arbitrage LLC sold $606.4K2026-03-23 · AQR Arbitrage LLC sold $433.6K2026-03-23 · AQR Arbitrage LLC sold $322.8K2026-03-23 · AQR Arbitrage LLC sold $285.2K2026-03-23 · AQR Arbitrage LLC sold $270.9K2026-03-23 · AQR Arbitrage LLC sold $112.1K2026-03-23 · AQR Arbitrage LLC sold $67.6K2026-03-20 · AQR CAPITAL MANAGEMENT LLC sold $49.7K2026-03-23 · AQR Arbitrage LLC sold $17.5K2026-03-23 · AQR Arbitrage LLC sold $11.4K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IBAC: institutional holders (13F)

13F holdings, latest reported quarter
JANE STREET GROUP, LLC
20,436 sh
$220.3K
Clear Street Group Inc.
219,961 sh
$204.5K
Wealthspring Capital LLC
851,160 sh
$97.9K
AQR Arbitrage LLC
732,521 sh
$86.8K
Polar Asset Management Partners Inc.
500,000 sh
$57.5K

Congress trades in IBAC

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IBAC planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

IBAC mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
The Merger Fund VL
$510 position · as of 2026-06-30
0.0%
The Merger Fund
$40.8K position · as of 2026-06-30
0.0%
AQR Diversified Arbitrage Fund
$5.2K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$49.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 4 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

IBAC financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
-0.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-2.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-092024-092023-09
Operating income-$748.9K-$524.0K-$6.8K
Net income$3.4M$1.9M-$6.8K
Operating cash flow-$1.3M-$821.0K-$207
Cash$428.7K$822.8K$52.6K
Buybacks$106.1Mn/an/a
SEC XBRL, fiscal years, as known on 2026-10-27

IBAC Stock Sonar score 3/7 axes

Find similar shapesCompare

IBAC ranks highest on risk and compliance (91st percentile) and profitability (82nd), and lowest on institutional and government (3rd), among Pharma & Biotech peers.

Profitability
82
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-0.6% · 81 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-2.8% · 83 pct, sector of 576
Institutional and government
3
Inputs
  • Funds adding, latest quarter4 · 3 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
91
Inputs
  • Short interest, % of float+0.2% · 91 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies